Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Arun, S. Bayraktar, Diane Liu, A. Barrera, D. Atchley, L. Pusztai, J. Litton, V. Valero, F. Meric-Bernstam, G. Hortobagyi, C. Albarracin (2011)
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 28
A. Templeton, Laura Gonzalez, F. Vera-Badillo, A. Tibau, R. Goldstein, B. Seruga, A. Srikanthan, A. Pandiella, E. Amir, A. Ocaña (2016)
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-RegressionPLoS ONE, 11
T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. Eisen, M. Rijn, S. Jeffrey, T. Thorsen, H. Quist, J. Matese, P. Brown, D. Botstein, P. Lønning, A. Børresen-Dale (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 98
T. Nestler, F. Haidl, M. Wittersheim, P. Dalvi, P. Paffenholz, S. Wagener-Ryczek, D. Pfister, M. Hellmich, R. Büttner, M. Odenthal, A. Heidenreich (2019)
Comprehensive analysis of metastatic seminoma germ cell tumors shows divergent expression of immune-related pathways.Journal of Clinical Oncology
T. Bevers, M. Helvie, E. Bonaccio, K. Calhoun, M. Daly, W. Farrar, J. Garber, R. Gray, C. Greenberg, R. Greenup, N. Hansen, Randall Harris, A. Heerdt, T. Helsten, L. Hodgkiss, Tamarya Hoyt, John Huff, L. Jacobs, C. Lehman, B. Monsees, Bethany Niell, Catherine Parker, M. Pearlman, L. Philpotts, L. Shepardson, M. Smith, M. Stein, L. Tumyan, Cheryl Williams, Mary Bergman, Rashmi Kumar (2018)
Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN, 16 11
C. Lord, A. Ashworth (2016)
BRCAness revisitedNature Reviews Cancer, 16
S. Lakhani, B. Gusterson, J. Jacquemier, J. Sloane, T. Anderson, M. Vijver, D. Venter, D. Venter, A. Freeman, A. Antoniou, L. McGuffog, E. Smyth, C. Steel, N. Haites, Rodney Scott, D. Goldgar, S. Neuhausen, P. Daly, W. Ormiston, R. McManus, S. Scherneck, B. Ponder, P. Futreal, J. Peto, D. Stoppa-Lyonnet, Y. Bignon, J. Struewing, D. Bishop, J. Klijn, P. Devilee, C. Cornelisse, C. Lasset, G. Lenoir, R. Barkardottir, V. Egilsson, U. Hamann, J. Chang-Claude, H. Sobol, Barbara Weber, D. Easton, Michael Stratton (2000)
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 3
J. Litton, M. Scoggins, K. Hess, B. Adrada, R. Murthy, S. Damodaran, S. DeSnyder, A. Brewster, C. Barcenas, V. Valero, G. Whitman, Jill Schwartz-Gomez, E. Mittendorf, A. Thompson, T. Helgason, N. Ibrahim, H. Piwnica-Worms, S. Moulder, B. Arun (2020)
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
A. Tutt, B. Kaufman, R. Gelber, E. Fadden, C. Goessl, G. Viale, A. Arahmani, D. Fumagalli, H. Azim, Wenting Wu, Anna Grocholewicz, J. Costantino, P. Rastogi, J. Garber, C. Geyer (2015)
OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).Journal of Clinical Oncology, 33
M. Burstein, A. Tsimelzon, Graham Poage, K. Covington, A. Contreras, S. Fuqua, Michelle Savage, K. Osborne, S. Hilsenbeck, Jenny Chang, G. Mills, C. Lau, P. Brown (2014)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast CancerClinical Cancer Research, 21
P. Cortazar, Lijun Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, S. Swain, Tatiana Prowell, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, R. Justice, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, L. Slaets, Shenghui Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Minckwitz (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 384
(2015)
Is the future of personalized therapy in triplenegative breast cancer based on molecular subtype? Oncotarget
M. Wood, J. Garber, C. Isaacs, S. Masood, I. Bedrosian, N. Tung, J. Chun, F. Schnabel, B. Arun (2019)
Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendationsThe Breast Journal, 25
Jeff Hall, Ming Lee, B. Newman, J. Morrow, L. Anderson, B. Huey, M. King (1990)
Linkage of early-onset familial breast cancer to chromosome 17q21.Science, 250 4988
B. Lehmann, Joshua Bauer, X. Chen, M. Sanders, A. Chakravarthy, Y. Shyr, J. Pietenpol (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.The Journal of clinical investigation, 121 7
M. Robson, S. Im, E. Senkus, Bing-he Xu, S. Domchek, N. Masuda, S. Delaloge, Wei Li, N. Tung, A. Armstrong, Wenting Wu, C. Goessl, S. Runswick, P. Conte (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationThe New England Journal of Medicine, 377
S. Alkhayyat, Muhammad Khan, Tauseef Ahmad, Haroon, Huma Tariq, M. Baig (2022)
A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genesMedicine, 101
F. Cardoso, E. Senkus, A. Costa, E. Papadopoulos, M. Aapro, F. André, N. Harbeck, B. Lopez, C. Barrios, J. Bergh, L. Biganzoli, C. Boers-Doets, M. Cardoso, L. Carey, J. Cortes, G. Curigliano, V. Diéras, N. Saghir, A. Eniu, L. Fallowfield, P. Francis, K. Gelmon, S. Johnston, B. Kaufman, S. Koppikar, I. Krop, M. Mayer, G. Nakigudde, B. Offersen, S. Ohno, O. Pagani, S. Paluch-Shimon, F. Penault-Llorca, A. Prat, H. Rugo, G. Sledge, D. Spence, C. Thomssen, D. Vorobiof, B. Xu, L. Norton, E. Winer (2018)
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†Annals of Oncology, 29
B. Weigelt, I. Comino-Méndez, Ino Bruijn, L. Tian, J. Meisel, I. Garcia-Murillas, C. Fribbens, R. Cutts, L. Martelotto, C. Ng, R. Lim, P. Selenica, S. Piscuoglio, C. Aghajanian, L. Norton, R. Murali, D. Hyman, L. Borsu, M. Arcila, J. Konner, J. Reis-Filho, R. Greenberg, M. Robson, N. Turner (2017)
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian CancerClinical Cancer Research, 23
Yaning Zhu, Jian Wu, Chengwan Zhang, Su’an Sun, Jian Zhang, Wenjie Liu, JianChao Huang, Zhihong Zhang (2016)
BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysisOncotarget, 7
(2019)
Veliparib plus carboplatin/paclitaxel in HER2-negative, germline brca-mutated advanced breast cancer
H. Han, V. Diéras, M Robson, M. Pálácova, P. Marcom, Agnes Jager, Igor Bondarenko, D. Citrin, M. Campone, M. Telli, S. Domchek, M. Friedlander, Bella Kaufman, Judy Garber, Y. Shparyk, E. Chmielowska, Erik Jakobsen, V. Kaklamani, W. Gradishar, C. Ratajczak, C. Nickner, Q. Qin, J. Qian, S. Shepherd, S. Isakoff, S. Puhalla (2018)
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II studyAnnals of Oncology, 29
A. Militello, T. Zielli, D. Boggiani, M. Michiara, N. Naldi, B. Bortesi, P. Zanelli, V. Uliana, S. Giuliotti, A. Musolino (2019)
Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature ReviewFrontiers in Oncology, 9
P. Fasching, C. Jackisch, K. Rhiem, A. Schneeweiss, P. Klare, C. Hanusch, J. Huober, T. Link, M. Untch, S. Schmatloch, C. Denkert, A. Stefek, C. Uleer, G. Doering, K. Engels, F. Seither, J. Blohmer, S. Loibl (2019)
GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HJournal of Clinical Oncology
A Tutt (2010)
10.1016/S0140-6736(10)60892-6Lancet, 376
J. Mateo, C. Lord, V. Serra, A. Tutt, A. Tutt, J. Balmaña, Marta Castroviejo-Bermejo, C. Cruz, A. Oaknin, S. Kaye, S. Kaye, J. Bono, J. Bono (2019)
A decade of clinical development of PARP inhibitors in perspectiveAnnals of Oncology, 30
N. Tung, B. Arun, M. Hacker, E. Hofstatter, D. Toppmeyer, S. Isakoff, V. Borges, R. Legare, C. Isaacs, A. Wolff, P. Marcom, E. Mayer, Paulina Lange, Andrew Goss, Colby Jenkins, I. Krop, E. Winer, S. Schnitt, J. Garber (2020)
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).Journal of clinical oncology : official journal of the American Society of Clinical Oncology
A. Prat, J. Parker, O. Karginova, C. Fan, C. Livasy, Jason Herschkowitz, Xiaping He, C. Perou (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Research : BCR, 12
E. Copson, T. Maishman, W. Tapper, R. Cutress, S. Greville-Heygate, S. Greville-Heygate, D. Altman, B. Eccles, S. Gerty, L. Durcan, L. Jones, David Evans, A. Thompson, P. Pharoah, D. Easton, A. Dunning, A. Hanby, S. Lakhani, R. Eeles, F. Gilbert, H. Hamed, S. Hodgson, P. Simmonds, L. Stanton, D. Eccles, D. Eccles (2018)
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort studyThe Lancet. Oncology, 19
P. Fasching, C. Jackisch, K. Rhiem, A. Schneeweiss, P. Klare, C. Hanusch, J. Huober, T. Link, M. Untch, S. Schmatloch, C. Denkert, A. Stefek, C. Uleer, G. Doering, K. Engels, F. Seither, J. Blohmer, S. Loibl (2016)
A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA.Journal of Clinical Oncology, 34
K. Kuchenbaecker, J. Hopper, D. Barnes, K. Phillips, T. Mooij, M. Roos-Blom, Sarah Jervis, F. Leeuwen, R. Milne, N. Andrieu, D. Goldgar, M. Terry, M. Rookus, D. Easton, A. Antoniou, L. McGuffog, D. Evans, D. Barrowdale, D. Frost, J. Adlard, K. Ong, L. Izatt, M. Tischkowitz, R. Eeles, R. Davidson, S. Hodgson, Steve Ellis, C. Noguès, C. Lasset, D. Stoppa-Lyonnet, J. Fricker, L. Faivre, P. Berthet, M. Hooning, L. Kolk, C. Kets, M. Adank, E. John, Wendy Chung, I. Andrulis, M. Southey, M. Daly, S. Buys, A. Osorio, C. Engel, K. Kast, R. Schmutzler, T. Caldés, A. Jakubowska, J. Simard, M. Friedlander, S. McLachlan, E. Macháčková, L. Foretova, Y. Tan, C. Singer, E. Oláh, A. Gerdes, B. Arver, H. Olsson (2017)
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 317
E. Hahnen, B. Lederer, J. Hauke, S. Loibl, S. Kröber, A. Schneeweiss, C. Denkert, P. Fasching, J. Blohmer, C. Jackisch, S. Paepke, B. Gerber, S. Kümmel, C. Schem, G. Neidhardt, J. Huober, K. Rhiem, S. Costa, J. Altmüller, C. Hanusch, H. Thiele, V. Müller, P. Nürnberg, T. Karn, V. Nekljudova, M. Untch, G. Minckwitz, R. Schmutzler (2017)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical TrialJAMA Oncology, 3
F. Bertucci, C. Ng, A. Patsouris, N. Droin, S. Piscuoglio, N. Carbuccia, J. Soria, A. Dien, Y. Adnani, M. Kamal, S. Garnier, G. Meurice, M. Jimenez, S. Dogan, B. Verret, M. Chaffanet, T. Bachelot, M. Campone, C. Lefeuvre, H. Bonnefoi, F. Dalenc, A. Jacquet, M. Filippo, N. Babbar, D. Birnbaum, T. Filleron, C. Tourneau, F. André (2019)
Genomic characterization of metastatic breast cancersNature, 569
L. Emens, S. Loi, H. Rugo, A. Schneeweiss, V. Diéras, H. Iwata, C. Barrios, M. Nechaeva, L. Molinero, A. Duc, R. Funke, S. Chui, A. Husain, E. Winer, S. Adams, P. Schmid (2019)
Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab +nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancerGeneral Session Abstracts
C. Cruz, A. Llop-Guevara, J. Garber, B. Arun, J. Fidalgo, A. Lluch, M. Telli, C. Fernandez, C. Kahatt, C. Galmarini, A. Soto-Matos, V. Alfaro, A. Haza, S. Domchek, S. Antolín, L. Vahdat, N. Tung, R. López, J. Arribas, A. Vivancos, J. Baselga, V. Serra, J. Balmaña, S. Isakoff (2018)
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment SubstudyJournal of Clinical Oncology, 36
J. Litton, H. Rugo, J. Ettl, S. Hurvitz, A. Gonçalves, Kyung-Hun Lee, L. Fehrenbacher, R. Yerushalmi, L. Mina, Miguel Martín, H. Roché, Y. Im, R. Quek, D. Markova, I. Tudor, A. Hannah, W. Eiermann, J. Blum (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationThe New England Journal of Medicine, 379
M. Wunderle, P. Gass, L. Häberle, Vivien Flesch, C. Rauh, M. Bani, C. Hack, M. Schrauder, S. Jud, J. Emons, R. Erber, A. Ekici, Juliane Hoyer, Georgia Vasileiou, C. Kraus, A. Reis, A. Hartmann, M. Lux, M. Beckmann, P. Fasching, A. Hein (2018)
BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patientsBreast Cancer Research and Treatment, 171
A. Tutt, H. Tovey, M. Cheang, S. Kernaghan, L. Kilburn, P. Gazinska, J. Owen, J. Abraham, S. Barrett, P. Barrett-Lee, Robert Brown, S. Chan, M. Dowsett, J. Flanagan, Lisa Fox, A. Grigoriadis, A. Gutin, C. Harper-wynne, M. Hatton, K. Hoadley, J. Parikh, P. Parker, C. Perou, R. Roylance, Vandna Shah, A. Shaw, I. Smith, K. Timms, A. Wardley, G. Wilson, C. Gillett, J. Lanchbury, A. Ashworth, N. Rahman, M. Harries, P. Ellis, S. Pinder, J. Bliss (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialNature Medicine, 24
S. Loibl, J. O’Shaughnessy, M. Untch, W. Sikov, H. Rugo, M. McKee, J. Huober, M. Golshan, G. Minckwitz, D. Maag, D. Sullivan, N. Wolmark, K. McIntyre, J. Lorenzo, O. Filho, P. Rastogi, W. Symmans, Xuan Liu, C. Geyer (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.The Lancet. Oncology, 19 4
S. Isakoff, E. Mayer, Lei He, T. Traina, L. Carey, K. Krag, H. Rugo, Minetta Liu, V. Stearns, S. Come, K. Timms, A. Hartman, D. Borger, D. Finkelstein, J. Garber, P. Ryan, E. Winer, P. Goss, L. Ellisen (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 17
H. Rugo, O. Olopade, A. DeMichele, C. Yau, L. Veer, M. Buxton, M. Hogarth, N. Hylton, M. Paoloni, J. Perlmutter, W. Symmans, D. Yee, A. Chien, A. Wallace, H. Kaplan, J. Boughey, T. Haddad, K. Albain, Minetta Liu, C. Isaacs, Q. Khan, J. Lang, Rebecca Viscusi, L. Pusztai, S. Moulder, S. Chui, K. Kemmer, A. Elias, Kirsten Edmiston, D. Euhus, B. Haley, R. Nanda, D. Northfelt, D. Tripathy, W. Wood, C. Ewing, R. Schwab, J. Lyandres, S. Davis, G. Hirst, A. Sanil, D. Berry, L. Esserman (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.The New England journal of medicine, 375 1
D. Pfister, K. Ang, D. Brizel (2012)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
K. Gelmon (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialBreast Diseases: A Year Book Quarterly, 22
K. Heinhuis, W. Ros, M. Kok, N. Steeghs, J. Beijnen, J. Schellens (2019)
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumorsAnnals of Oncology, 30
Fatima Cardoso, A. Costa, E. Senkus, M. Aapro, F. André, C. Barrios, J. Bergh, G. Bhattacharyya, L. Biganzoli, M. Cardoso, L. Carey, D. Corneliussen-James, G. Curigliano, V. Diéras, N. Saghir, A. Eniu, L. Fallowfield, D. Fenech, P. Francis, K. Gelmon, A. Gennari, N. Harbeck, C. Hudis, B. Kaufman, I. Krop, M. Mayer, H. Meijer, S. Mertz, S. Ohno, O. Pagani, E. Papadopoulos, F. Peccatori, F. Penault-Llorca, M. Piccart, J. Pierga, H. Rugo, L. Shockney, G. Sledge, S. Swain, C. Thomssen, A. Tutt, D. Vorobiof, Bing-he Xu, L. Norton, Eric Winer (2016)
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Annals of Oncology, 28
S. Loibl, K. Weber, K. Timms, E. Elkin, E. Hahnen, P. Fasching, B. Lederer, C. Denkert, A. Schneeweiss, Stephan Braun, C. Salat, M. Rezai, J. Blohmer, D. Zahm, C. Jackisch, B. Gerber, P. Klare, S. Kümmel, C. Schem, S. Paepke, R. Schmutzler, K. Rhiem, S. Penn, J. Reid, V. Nekljudova, A-R Hartman, G. Minckwitz, M. Untch (2018)
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixtoAnnals of Oncology, 29
P. Schmid, S. Adams, H. Rugo, A. Schneeweiss, C. Barrios, H. Iwata, V. Diéras, R. Hegg, S. Im, G. Wright, V. Henschel, L. Molinero, S. Chui, R. Funke, A. Husain, E. Winer, S. Loi, L. Emens (2018)
Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast CancerThe New England Journal of Medicine, 379
K. Miller, Y. Tong, David Jones, T. Walsh, M. Danso, Cynthia Ma, P. Silverman, M. King, S. Badve, S. Perkins (2015)
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146.Journal of Clinical Oncology, 33
H. Farmer, N. Mccabe, C. Lord, A. Tutt, Damian Johnson, T. Richardson, M. Santarosa, Krystyna Dillon, I. Hickson, C. Knights, N. Martin, S. Jackson, G. Smith, A. Ashworth (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 434
M. Robson, N. Tung, P. Conte, S. Im, E. Senkus, Bing-he Xu, N. Masuda, S. Delaloge, Wei Li, A. Armstrong, Wenting Wu, C. Goessl, S. Runswick, S. Domchek (2019)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerAnnals of Oncology, 30
(2019)
NCCN guidelines : Genetic/familial high risk assessment: breast , ovarian, and pancreatic
Ju-Bo Zhang, Ying Lin, X. Sun, Biyun Wang, Z. Wang, Jian-feng Luo, Leiping Wang, Su-shan Zhang, Junning Cao, Z. Tao, Junlong Wu, Z. Shao, Wentao Yang, X. Hu (2018)
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancerAnnals of Oncology, 29
J. Abraham, A. Vallier, W. Qian, L. Grybowicz, S. Thomas, S. Mahmud, C. Harvey, K. McAdam, L. Hughes-Davies, R. Roylance, E. Copson, Jessica Brown, E. Provenzano, M. Tischkowitz, H. Earl (2017)
Abstract OT2-01-15: PARTNER - Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patientsCancer Research, 77
D. Atchley, C. Albarracin, Adriana López, V. Valero, Chris Amos, A. González-Angulo, G. Hortobagyi, B. Arun (2008)
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 26
M. Audeh, J. Carmichael, R. Penson, M. Friedlander, B. Powell, K. Bell-McGuinn, C. Scott, J. Weitzel, A. Oaknin, N. Loman, K. Lu, R. Schmutzler, U. Matulonis, M. Wickens, A. Tutt (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 376
N. Turner, A. Tutt, A. Ashworth (2004)
Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 4
P. Pilié, Chad Tang, G. Mills, T. Yap (2018)
State-of-the-art strategies for targeting the DNA damage response in cancerNature Reviews Clinical Oncology, 16
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Purpose of ReviewDetection of BRCA germline mutations (gBRCAm) impacts breast cancer medical treatment—according to differential sensitivity to cytotoxic chemotherapy and the activity of PARP inhibitors—and not only familial prevention. Guidelines for genetic testing—initially mainly based on familial history, age, and triple negative breast cancer (TNBC) subtype—currently are expanding in order to offer new therapeutic options.Recent FindingsIn the early setting, gBRCAm patients present a similar outcome as the non-carrier population with standard neoadjuvant chemotherapy, and the role of platinum chemotherapy is still a matter of debate. In metastatic setting, international guidelines recommend the use of platinum-based chemotherapy in gBRCAm patients and more broadly in TNBC patients.SummaryOlaparib and talazoparib monotherapy are approved in metastatic gBRCAm breast cancer. To date, it remains unclear how the combination of platinum-based regimen and PARP inhibitors should be sequenced.
Current Breast Cancer Reports – Springer Journals
Published: Jun 6, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.